Publications by authors named "J Marolleau"
Article Synopsis
- Vitreoretinal lymphoma (VRL) has a poor prognosis due to high relapse rates in the central nervous system, requiring treatments like high-dose chemotherapy with autologous stem cell transplantation (HCT-ASCT).
- A study analyzed 38 adult patients treated with HCT-ASCT for isolated VRL over 11 years, showing that 84% received a thiotepa-based regimen, with some patients experiencing serious side effects.
- Results revealed a significant relapse rate, particularly in the brain, but the strategy showed relatively good median survival rates: 96 months for progression-free survival and 92 months overall.
In an open prospective, multicenter study enrolling 48 selected patients with chronic immune thrombocytopenia who achieved complete response for 1 year on thrombopoietin receptor agonists, half of the patients maintained a sustained response off treatment 4 years after treatment discontinuation.
View Article and Find Full Text PDFArticle Synopsis
- Recto-colic graft-versus-host disease (GVHD) is a common post-transplant complication, and the study aimed to establish histological markers for diagnosis and prognosis.
- A total of 119 patients were reviewed; 67 had confirmed GVHD, identified by higher counts of apoptotic bodies (AB) in biopsies, with significant differences in staining methods.
- A diagnostic threshold of 4 AB per 10 crypts signals GVHD, while more than 8 AB indicates a poor prognosis, with additional findings of eosinophilic cell-lining in glands suggesting further diagnostic potential.
Introduction: Hematopoietic stem cell transplantation (HCST) is a widely used therapy in the management of hematological malignancies, leading to cytopenias that require transient transfusions. Platelet recovery (PR) following HSCT is assessed by monitoring platelet count (PC). Immature platelet fraction (IPF) is a research parameter offered by Sysmex® on XN series analyzers, enabling rapid diagnostic orientation in the event of thrombocytopenia.
View Article and Find Full Text PDFA second autologous stem-cell transplantation (ASCT2) is considered for relapsed multiple myeloma (RMM) patients showing prolonged response after a first ASCT. However, given breakthrough treatments like anti-CD38 and immunotherapy, its role remains debated. We conducted a real-life study in 10 French centers (1996-2017) involving 267 RMM patients receiving ASCT2.
View Article and Find Full Text PDF